middle.news
Proteomics International Secures US Patent for Breakthrough Esophageal Cancer Test
8:42am on Wednesday 17th of December, 2025 AEDT
•
Healthcare
Read Story
Proteomics International Secures US Patent for Breakthrough Esophageal Cancer Test
8:42am on Wednesday 17th of December, 2025 AEDT
Key Points
US patent granted for PromarkerEso diagnostic test
Patent protection extends to Australia, China, Hong Kong, Europe, and USA
PromarkerEso enables early, non-invasive detection of esophageal adenocarcinoma
Addresses major unmet need with 90% of cases currently undetected until late stage
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Proteomics International Laboratories (ASX:PIQ)
OPEN ARTICLE